

CORRECTION

Open Access



Correction to: Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials

Tatjana Welzel^{1,2*}, Carolyn Winskill³, Nancy Zhang³, Andreas Woerner² and Marc Pfister^{1,3}

Correction to: *Pediatr Rheumatol* 19, 46 (2021)
<https://doi.org/10.1186/s12969-021-00514-4>

Following publication of the original article [1], the authors identified some errors in the text of the article. Correct text parts should be as follows:

1. Results section in Abstract should read as follows: All 35 RCTs reported efficacy while 34/35 provided safety outcomes and 16/35 provided pharmacokinetic data.
2. Table 4 should have IL-1 inhibitor canakinumab 4mg/kg single dose
3. Results section text should be as follows: In march 2020, the FDA has approved all 23 reviewed drugs, including bDMARDs and JAK inhibitors for adult rheumatology, whereas the EMA has approved 22 (Table 6).

Author details

¹Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB), University of Basel, Spitalstrasse 33, CH 4031 Basel, Switzerland. ²Paediatric Rheumatology, University Children's Hospital Basel (UKBB), University of Basel, Basel, Switzerland. ³Integrated Drug Development, Certara LP, Princeton, NJ, USA.

Published online: 16 August 2021

Reference

1. Welzel, et al. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials. *Pediatr Rheumatol.* 2021;19:46. <https://doi.org/10.1186/s12969-021-00514-4>.

The original article can be found online at <https://doi.org/10.1186/s12969-021-00514-4>.

* Correspondence: Tatjana.Welzel@ukbb.ch

¹Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB), University of Basel, Spitalstrasse 33, CH 4031 Basel, Switzerland

²Paediatric Rheumatology, University Children's Hospital Basel (UKBB), University of Basel, Basel, Switzerland

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.